Jennifer A. Fox - 15 Jun 2026 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Reporting relationship: Chief Business Officer and Chief Financial Officer
Issuer ticker: ZBIO
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 18:00:11 UTC
Prior SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Jeffrey Held, Attorney-in-Fact

Key filing fact

Jennifer A. Fox filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 17 Jun 2026.

Key facts

This page summarizes Jennifer A. Fox's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 18:00.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001841557 Primary reporting owner

Fox Jennifer A.

Relationship: Chief Business Officer and Chief Financial Officer
Address: C/O ZENAS BIOPHARMA, INC., 852 WINTER ST., SUITE 250, WALTHAM
Signature: By: /s/ Jeffrey Held, Attorney-in-Fact
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZBIO transaction

Common Stock

Award

Transaction value
Shares: +1,592
Change %
Price: $13.35^*
Shares after: 1,592
Date: 05 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +125,000
Change %
Price: $0.000000^*
Shares after: 125,000
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $18.71
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026 in transactions that were exempt under Rule 16b-3(c).

Footnote F2

The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

SEC remarks

Chief Business Officer and Chief Financial Officer